Search for: "Robin Feldman" Results 41 - 60 of 135
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
9 Oct 2022, 6:00 pm by Juvan Bonni
Robin Feldman: Rewarding Failure with Patents (Source: SSRN) New Job Postings on Patently-O: Venable LLP Casimir Jones, S.C. [read post]
8 Aug 2021, 7:53 pm by Juvan Bonni
 Jie Fei (Christina) Pan: Supreme Court of Canada Denies Amgen Leave to Appeal Decision Invalidating its Filgrastim Patent (Source: JD Supra) Susan Decker and Matthew Bultman: Apple Sinks ‘Submarine Patent,’ Escapes $308.5 Million Verdict (Source: Bloomberg) Commentary and Journal Articles: Robin Feldman: Our Patent System is Broken. [read post]
15 Oct 2015, 11:04 am
" Robin Bravender of Greenwire reports that "Justices question regulators' reach in fight over energy rule. [read post]
29 May 2013, 7:07 am by Lisa Larrimore Ouellette
Here's an updated list of the most downloaded IP papers that were posted on SSRN in the past 60 days (with notes about the ones that were not on last month's list):The AIA 500 Expanded: Effects of Patent Monetization Entities, by Robin Feldman, Thomas Ewing & Sara JerussReview of Canadian University Fair Dealing Policies, by Lisa Di Valentino (the title is a pretty good summary)A Simple Approach to Setting Reasonable Royalties for Standard-Essential Patents, by Mark Lemley… [read post]
9 May 2017, 2:37 pm by Mike Mireles
[emphasis added]The EFF’s program is based on research by Professor Robin Feldman concerning Intellectual Ventures relationship with universities. [read post]
8 Jul 2016, 4:59 am by Amy Howe
”  At Empirical SCOTUS, Adam Feldman continues his review of the Term, this time focusing on how law firms fared at the Court. [read post]
16 Jan 2014, 6:01 pm by Colin O'Keefe
Also, over on LXBN, Dana Frix joins me to talk about AT&T’s new “Sponsored Data” feature and we have a piece on some progress in the Marvin Gaye/Robin Thicke copyright dispute. [read post]
18 Jul 2020, 12:08 pm by mes286
  The panel consisted of presentations by: Dorit Reiss on the dilemmas involved in the rush to create a COVID-19 vaccine; Robin Feldman on health care access and trust in health care information during COVID-19; Hadar Aviram on why California prisons are so vulnerable to COVID-19, and what to do about it; and John Crawford on the steps the Fed has taken to try to mitigate the economic impacts of the pandemic. [read post]
21 Apr 2013, 1:39 pm by Lisa Larrimore Ouellette
Here's an updated list of the most downloaded IP papers that were posted on SSRN in the past 60 days:The AIA 500 Expanded: Effects of Patent Monetization Entities, by Sara Jeruss, Robin Feldman & Thomas Ewing (this study of 13,000 patent cases over 4 years has gotten lots of press; see press release, Thomson Reuters, Law.com, IPWatchdog)The Securitization of Patents, by Michael Risch (see guest post by author on PatentlyO)Patent Trolls by the Numbers, by Colleen V. [read post]
6 Feb 2013, 5:40 pm by Lisa Larrimore Ouellette
Myriad http://j.mp/WMc72z  Michael Carrier on 6 possible antitrust actions against Patent Assertion Entities (new on SSRN) http://j.mp/WYxz2l Fascinating Book Club on Merges's Justifying IP at PrawfsBlawg http://j.mp/UCqw0z New on SSRN: Understanding Trademark Strength by Timothy Greene & Jeffrey Wilkerson http://j.mp/UB86gBIntellectual Property Law Without Secrets by David Levine :: SSRN http://j.mp/10ZZaB9Highly recommended: "Establishing an Island of Patent Sanity" by Oskar… [read post]
12 Nov 2012, 8:33 am by Lisa Larrimore Ouellette
Colleen Chien still tops the list of the most downloaded IP papers that were posted on SSRN in the past 60 days:Startups and Patent Trolls, by Colleen Chien (also see her "Ten Ways Startups Can Deal with Patent Troll Demands")The America Invents Act 500: Effects of Patent Monetization Entities on US Litigation, by Sara Jeruss, Robin Cooper Feldman, and Joshua Walker (using the same data as the forthcoming GAO report on NPEs/PAEs/PMEs/trolls or whatever they are… [read post]
3 Nov 2010, 6:55 pm by Kate Bladow
Thursday's posts are as follows:  2010 World Pro Bono Week — Houston Law Firms & Corporations Team Up to Provide Pro Bono to Houston Community - Elizabeth Black Berry, Weil Gotshal & Manges LLP at 3 Geeks & a Law Blog An Epic Journey - Tim Eigo, AZ Attorney Celebrating National Pro Bono Week - David Curcio, Jackson Walker LLP at 3 Geeks & a Law Blog Celebrating National Pro Bono Week: Feldman Shepherd - Amanda Walsh, The PR Lawyer … [read post]
31 Jan 2012, 7:29 am by Matt Osenga
In a new study with results recently published in the Stanford Technology Law Review, Tom Ewing and Robin Feldman, law professor at the University of California-Hastings, discuss specifically the case of Intellectual Ventures and patent mass aggregators. [read post]
16 Jul 2010, 1:39 pm by scanner1
KANTOROWICZ and CHARLOTTE KANTOROWICZ; JAMES FELDMAN and COURTNEY FELDMAN; DAVID P. [read post]
25 May 2010, 4:36 pm by Wendy Hickok Robinson
Feldman, United States Magistrate Judge Karen Wells Roby, Civil District Court Judge Robin M. [read post]
29 Dec 2011, 6:43 am by christopher
., and Robin Feldman, J.D. detail the copyright regime ringed around the seminal Mini–Mental State Examination (MMSE) and the aggressive enforcment of that copyright against open source competitors such as the Sweet 16 — a 16-item assessment of thinking, learning, and memory developed by Harvard’s Tamara Fong. [read post]
5 Sep 2016, 11:23 am
This time it was asked by two of America’s most prominent scholars of the patent system, Professor Robin Feldman of the University of California Hastings College of Law and Professor Mark Lemley of Stanford University, in their article, “Do Patent Licensing Demands Mean Innovation”, Iowa Law Review, November 2015. [read post]
22 Aug 2013, 2:01 pm
Patent troll expert Professor Robin Feldman of UC Hastings said that patent rights are not the same as other property rights. [read post]
25 Jul 2016, 3:06 am by Amy Howe
” At Empirical SCOTUS, Adam Feldman looks at the role of Supreme Court specialists in the upcoming Term. [read post]
Robin Feldman, of UC College of the Law focused on statements pharmaceutical companies make to FDA and the USPTO. [read post]